Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - HESKA CORPFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - HESKA CORPR3.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR5.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR4.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR2.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR8.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR1.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR7.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR6.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR9.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR21.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR18.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR17.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR16.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR12.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR19.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR20.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR14.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR13.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR15.htm
EX-31.2 - CFO CERTIFICATION - HESKA CORPex31-2.htm
EX-31.1 - CEO CERTIFICATION - HESKA CORPex31-1.htm
10-Q - FORM 10Q - HESKA CORPform10q.htm
XML - IDEA: XBRL DOCUMENT - HESKA CORPR11.htm
EX-32.1 - CEO AND CFO CERTIFICATION - HESKA CORPex32-1.htm
v2.4.0.6
SEGMENT REPORTING
9 Months Ended
Sep. 30, 2012
Notes to Financial Statements  
SEGMENT REPORTING

4. SEGMENT REPORTING

The Company is comprised of two reportable segments, Core Companion Animal Health ("CCA") and Other Vaccines, Pharmaceuticals and Products ("OVP"). The CCA segment includes diagnostic instruments and supplies, as well as single use diagnostic and other tests, pharmaceuticals and vaccines, primarily for canine and feline use. These products are sold directly by the Company as well as through other distribution relationships. CCA segment products manufactured at the Des Moines, Iowa production facility included in our OVP segment's assets are transferred at cost and are not recorded as revenue for our OVP segment. The OVP segment includes private label vaccine and pharmaceutical production, primarily for cattle, but also for other animals including small mammals and fish. All OVP products are sold by third parties under third-party labels.

 

Summarized financial information concerning the Company's reportable segments is shown in the following table (in thousands):

 

 

 

Core

Companion

Animal Health

 

 

Other Vaccines,

Pharmaceuticals

and Products

 

 

 

 

Total

Nine Months Ended

September 30, 2011:

Total  revenue $ 44,727   $ 9,833     $ 54,560  
Operating income   1,379     1,456       2,835  
Interest expense   107     17       124  
Total assets   52,528     10,494       63,022  
Net assets   40,743     7,190       47,933  
Capital expenditures   218     404       622  
Depreciation and amortization   985     643       1,628  
 

Nine Months Ended

September 30, 2012:

 
Total  revenue $ 45,811   $ 8,541     $ 54,352  
Operating income   883     555       1,438  
Interest expense   68      20        88  
Total assets   51,194     11,784       62,978  
Net assets   39,286     9,085       48,371  
Capital expenditures   429     476       905  
Depreciation and amortization   622     649       1,271  
                         

 

 

 

Core

Companion

Animal Health

 

 

Other Vaccines,

Pharmaceuticals

and Products

 

 

 

 

Total

Three Months Ended

September 30, 2011:

Total  revenue $ 14,263   $ 3,345     $ 17,608  
Operating income   174     234       408  
Interest expense   68     1       69  
Total assets   52,528     10,494       63,022  
Net assets   40,743     7,190       47,933  
Capital expenditures   52     125       177  
Depreciation and amortization   292     218       510  
 

Three Months Ended

September 30, 2012:

 
Total  revenue $ 13,530   $ 3,376     $ 16,906  
Operating income (loss)   (126)   99       (27)
Interest expense    21      8        29  
Total assets   51,194     11,784       62,978  
Net assets   39,286     9,085       48,371  
Capital expenditures   194     169       363  
Depreciation and amortization   213     197       410